{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Platinol&page=23", "query": { "intervention": "Platinol", "page": 23 }, "page_size": 10 }, "pagination": { "page": 23, "page_size": 10, "total_count": 1786, "total_pages": 179, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Platinol&page=24&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Platinol&page=22&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T17:12:56.079Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03515538", "title": "Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Oral Mucositis" ], "interventions": [ { "name": "RRx-001", "type": "DRUG" }, { "name": "Cisplatin for injection", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "EpicentRx, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2018-07-12", "completion_date": "2020-10-08", "has_results": true, "last_update_posted_date": "2024-11-04", "last_synced_at": "2026-11-15T17:12:56.079Z", "location_count": 12, "location_summary": "Santa Monica, California • Denver, Colorado • Washington D.C., District of Columbia + 9 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03515538" }, { "nct_id": "NCT00001332", "title": "Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Escalating Dose I.P. Platinum for Gastrointestinal Peritoneal Carcinomatosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Peritoneal Neoplasms", "Stomach Neoplasms" ], "interventions": [ { "name": "CHPP with cisplatin", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 50, "start_date": "1992-12", "completion_date": "2000-10", "has_results": false, "last_update_posted_date": "2008-03-04", "last_synced_at": "2026-11-15T17:12:56.079Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001332" }, { "nct_id": "NCT06140407", "title": "Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Limited Stage Lung Small Cell Carcinoma", "Stage I Lung Cancer", "Stage II Lung Cancer", "Stage III Lung Cancer" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE", "RADIATION" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2024-02-14", "completion_date": "2025-05-27", "has_results": false, "last_update_posted_date": "2025-06-05", "last_synced_at": "2026-11-15T17:12:56.079Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06140407" }, { "nct_id": "NCT06535607", "title": "Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)", "Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)", "Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)", "Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)", "Sub-study 5 Unresectable Pleural Mesothelioma (Volrustomig Monotherapy)" ], "interventions": [ { "name": "Volrustomig", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 257, "start_date": "2024-08-22", "completion_date": "2028-11-30", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-11-15T17:12:56.079Z", "location_count": 6, "location_summary": "Los Angeles, California • Baltimore, Maryland • New York, New York + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "Stony Brook", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06535607" }, { "nct_id": "NCT02672865", "title": "Adjuvant Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Gastric Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Malignant Neoplasm", "Gastric Cancer" ], "interventions": [ { "name": "Hyperthermic Intraperitoneal Chemotherapy (HIPEC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Loma Linda University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 4, "start_date": "2016-02-02", "completion_date": "2018-10-03", "has_results": false, "last_update_posted_date": "2019-04-12", "last_synced_at": "2026-11-15T17:12:56.079Z", "location_count": 1, "location_summary": "Loma Linda, California", "locations": [ { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02672865" }, { "nct_id": "NCT04610671", "title": "Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Muscle-Invasive Bladder Carcinoma", "Bladder Cancer" ], "interventions": [ { "name": "CG0070", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2020-10-26", "completion_date": "2024-07-25", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-11-15T17:12:56.079Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04610671" }, { "nct_id": "NCT03635567", "title": "Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cervical Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Placebo to pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 617, "start_date": "2018-10-25", "completion_date": "2024-06-04", "has_results": true, "last_update_posted_date": "2026-02-04", "last_synced_at": "2026-11-15T17:12:56.079Z", "location_count": 20, "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Orange, California + 15 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03635567" }, { "nct_id": "NCT07090499", "title": "A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced/Metastatic Solid Tumors", "Bladder Cancer", "Urothelial Carcinoma", "Advanced Non-Small Cell Lung Cancer", "Carcinoma, Non Small Cell Lung", "Carcinoma, Squamous Cell of Head and Neck", "Head and Neck Cancer", "Esophageal Cancer", "Gastroesophageal Junction Adenocarcinoma", "Esophageal Squamous Cell Carcinoma", "Esophageal Adenocarcinoma", "Pancreatic Adenocarcinoma", "Pancreatic Cancer" ], "interventions": [ { "name": "PF-08046876", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "COMBINATION_PRODUCT" }, { "name": "Cisplatin", "type": "COMBINATION_PRODUCT" }, { "name": "Carboplatin", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 540, "start_date": "2025-08-20", "completion_date": "2029-07-08", "has_results": false, "last_update_posted_date": "2026-11-05", "last_synced_at": "2026-11-15T17:12:56.079Z", "location_count": 21, "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 11 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07090499" }, { "nct_id": "NCT07869836", "title": "BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Urothelial Cancer", "Metastatic Urothelial Cancer", "Bladder Cancer", "Bladder Cancer (BC)", "Bladder (Urothelial, Transitional Cell) Cancer", "Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable", "Bladder Ca", "Bladder Cancer Recurrent", "Bladder Cancer Stage IV", "Urothelial Carcinoma Bladder", "Urothelial Carcinoma Recurrent", "Urothelial Carcinoma of the Urinary Bladder" ], "interventions": [ { "name": "T-Bren, Dose level 1", "type": "DRUG" }, { "name": "T-bren, Dose level 2", "type": "DRUG" }, { "name": "Gemcitabine + Platinum Based Chemotherapy (Cisplatin or Carboplatin)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SystImmune Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 520, "start_date": "2026-11", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-11-10", "last_synced_at": "2026-11-15T17:12:56.079Z", "location_count": 1, "location_summary": "Macon, Georgia", "locations": [ { "city": "Macon", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07869836" }, { "nct_id": "NCT02576574", "title": "Avelumab in First-line NSCLC (JAVELIN Lung 100)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "First Line Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Avelumab Weekly", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1214, "start_date": "2015-10-29", "completion_date": "2024-01-29", "has_results": true, "last_update_posted_date": "2025-01-31", "last_synced_at": "2026-11-15T17:12:56.079Z", "location_count": 21, "location_summary": "Huntsville, Alabama • Surprise, Arizona • San Diego, California + 18 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Surprise", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Boynton Beach", "state": "Florida" }, { "city": "Valdosta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02576574" } ] }